2. Academic Validation
  3. Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3

Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3

  • Bioorg Med Chem. 2008 May 1;16(9):4954-62. doi: 10.1016/j.bmc.2008.03.036.
Mohamed Ettaoussi 1,  Basile Péres,  Fréderique Klupsch,  Philippe Delagrange,  Jean-A Boutin,  Pierre Renard,  Daniel-H Caignard,  Philippe Chavatte,  Pascal Berthelot,  Daniel Lesieur,  Saïd Yous
Affiliations

Affiliation

  • 1 Laboratoire de Chimie Thérapeutique (EA 1043), Faculté des Sciences Pharmaceutiques et Biologiques, Université de Lille, 3, rue du professeur Laguesse, 2, BP 83, 59006 Lille Cedex, France.
PMID: 18372181 DOI: 10.1016/j.bmc.2008.03.036
Abstract

Benzofuranic analogues of MCA-NAT (5-methoxycarbonylamino-N-acetyltryptamine) have been synthesized and evaluated as Melatonin Receptor ligands. Introduction of a methoxycarbonylamino substituent in the C-5 position of the benzofurane nucleus obtains MT(3) selective ligands. This selectivity can be modulated with suitable variations of the C-5 position and the acyl group on the C-3 side chain.

Figures